Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - amlodipine - tablet - 10 milligram(s) - dihydropyridine derivatives; amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - amlodipine - tablet - 5 milligram(s) - dihydropyridine derivatives; amlodipine

Zimbabwe - English - Medicines Control Authority

pfizer laboratories (pty) ltd - varenicline tartrate - tablet, coated; oral - 0.5; 1mg

United States - English - NLM (National Library of Medicine)

r-pharm us operating, llc - ixabepilone (unii: k27005np0a) (ixabepilone - unii:k27005np0a) - ixabepilone 15 mg in 15 mg - ixempra is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see clinical studies ( 14)]. ixempra is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see clinical studies ( 14)]. ixempra is contraindicated in patients who have: - a neutrophil count <1500 cells/mm 3 or a platelet count <100,000 cells/mm 3 [see warnings and precautions (